Microparticles in NASH: origins, pathogenic roles, and biomarker of disease activity

NASH 中的微粒：起源、致病作用和疾病活动的生物标志物

• 批准号: nhmrc : 1044288
• 负责人: Prof Geoffrey Farrell
• 金额: $ 36.05万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/microparticles-nash-origins-disease-activity/111645
• 关键词: Microparticles; NASH; origins; pathogenic; roles

30% of Australians have non-alcoholic fatty liver disease (NAFLD). Cirrhosis is the third cause of death; only 10-25% of NAFLD livers show steatohepatitis (NASH), which leads to cirrhosis. We have found that microparticles (MPs), small fragments of cell membranes, circulate in NASH but not in ordinary fatty liver. We will now explore ways in which MPs incite inflammation and liver fibrosis in NASH, and design new tests based on MPs to improve clinical assessment of patients with NAFLD/NASH.

30%的澳大利亚人患有非酒精性脂肪肝（NAFLD）。肝硬化是第三大死因；只有10-25%的NAFLD患者表现为导致肝硬化的脂肪性肝炎（NASH）。我们发现微粒（MPs），细胞膜的小碎片，在NASH中循环，但在普通脂肪肝中没有。我们现在将探索MPs在NASH中刺激炎症和肝纤维化的途径，并设计基于MPs的新测试，以改善NAFLD/NASH患者的临床评估。